JAHA:肺动脉高压儿童和青年人心导管检查主要早期不良事件的危险因素!

2018-03-01 xing.T MedSci原创

由此可见,青年PH患者是诊断性和介入性心导管检查的高危人群。医院处理PH的经验与与降低的风险相关,独立于总的心导管病例数量。

心导管检查是肺动脉高压患者评估和随访的金标准。到目前为止,关于这一人群中进行心导管检查后发生灾难性不良事件危险因素的数据十分有限。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员进行了一项回顾性多中心队列研究来评估儿童和青年人心导管检查后发生灾难性不良后果的风险,并确定这些结局的危险因素。研究人员分析了在2011年1月1日至2015年12月31日期间所有接受心导管检查的年龄为0岁到21岁的儿童和年轻成人。采用混合效应多变量回归分析评估预设的受试者、操作和中心层面协变量与死亡、心脏骤停和心导管检查期间或之后需要机械辅助循环风险之间相关性。

研究人员在77个中心共对7729名受试者中进行的8111次心导管检查进行了分析。所观察到的综合结局风险为1.4%,出院前死亡的风险为5.2%。在早产新生儿和非早产婴儿进行心导管检查与灾难性的不良事件风险增加相关,在进行心导管检查前采用正性肌力药治疗和降低全身动脉血氧饱和度的患者中也一样。次要分析表明:(1)医院对PH患者增加的心导管检查数量与降低综合结局风险相关(比值比为,每10次心导管检查为0.8,P=0.002)和(2)肺血管阻力和肺动脉压增加与风险增加有关(P<0.0001)。

由此可见,青年PH患者是诊断性和介入性心导管检查的高危人群。医院处理PH的经验与与降低的风险相关,独立于总的心导管病例数量。

原始出处:


Michael L. O'Byrne,et al. Risk Factors for Major Early Adverse Events Related to Cardiac Catheterization in Children and Young Adults With Pulmonary Hypertension: An Analysis of Data From the IMPACT (Improving Adult and Congenital Treatment) Registry.JAHA.2018. https://doi.org/10.1161/JAHA.117.008142

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916800, encodeId=fa4c191680038, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Sun Apr 08 18:00:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925223, encodeId=f2b51925223db, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Oct 04 16:00:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294849, encodeId=58dc294849f9, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:56:25 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267748, encodeId=c37c126e7486d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 02 15:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050786, encodeId=f6281050e864e, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Mar 01 03:00:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-04-08 zll0625
  2. [GetPortalCommentsPageByObjectIdResponse(id=1916800, encodeId=fa4c191680038, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Sun Apr 08 18:00:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925223, encodeId=f2b51925223db, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Oct 04 16:00:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294849, encodeId=58dc294849f9, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:56:25 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267748, encodeId=c37c126e7486d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 02 15:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050786, encodeId=f6281050e864e, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Mar 01 03:00:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1916800, encodeId=fa4c191680038, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Sun Apr 08 18:00:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925223, encodeId=f2b51925223db, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Oct 04 16:00:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294849, encodeId=58dc294849f9, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:56:25 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267748, encodeId=c37c126e7486d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 02 15:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050786, encodeId=f6281050e864e, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Mar 01 03:00:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-10 owlhealth

    不错耶.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1916800, encodeId=fa4c191680038, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Sun Apr 08 18:00:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925223, encodeId=f2b51925223db, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Oct 04 16:00:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294849, encodeId=58dc294849f9, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:56:25 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267748, encodeId=c37c126e7486d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 02 15:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050786, encodeId=f6281050e864e, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Mar 01 03:00:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-02 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=1916800, encodeId=fa4c191680038, content=<a href='/topic/show?id=f24198994a6' target=_blank style='color:#2F92EE;'>#青年人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98994, encryptionId=f24198994a6, topicName=青年人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Sun Apr 08 18:00:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1925223, encodeId=f2b51925223db, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Oct 04 16:00:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294849, encodeId=58dc294849f9, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 10:56:25 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267748, encodeId=c37c126e7486d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 02 15:00:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050786, encodeId=f6281050e864e, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Thu Mar 01 03:00:00 CST 2018, time=2018-03-01, status=1, ipAttribution=)]
    2018-03-01 明天jing

    肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。

    0

相关资讯

Hypertension:肺动脉高压的发病新机制!

肺动脉内皮细胞的增殖紊乱和血管生成是肺动脉高压发展的重要阶段。最近的研究显示GDF11(生长分化因子11)可以诱导内皮细胞增殖和迁移;然而,GDF11是否直接参与了肺动脉高压的发病机制尚不清楚。近期,一项发表在杂志Hypertension上的研究发现GDF11在2个实验性肺动脉高压模型和培养的肺动脉内皮细胞中出现显着的上调和活化。正如在右心室肥大,右心室收缩压,血液动力学,心脏功能和血管重塑中所证

Am J Kidney Dis:CKD和ESRD患者的肺动脉高压与死亡率和心血管疾病相关性分析!

由此可见,CKD和ESRD患者的肺动脉高压与死亡和心血管事件风险显著增加有关。接受透析的ESRD患者与1-5期CKD患者相比风险更高。理解降低肺动脉压力的干预措施对这些患者存活率的影响需要进行随机对照试验来评估。

Int J Cardiol:肝纤维化标志物IV型胶原蛋白7S结构域在肺动脉高压患者中的应用!

由此可见,血清P4NP 7S与PH患者较高的中心静脉压、右侧容积超负荷和死亡率有关。

JAHA:先天性心脏病合并肺动脉高压患者的肺功能、炎症及内皮素1水平分析!

由此可见,CHD-APAH患者炎症生物标志物水平升高。呼吸道生理的显著异常可能导致呼吸困难,但不受循环和痰液细胞因子的影响。增加的血清内皮素-1和气道功能障碍之间的关系可能与支气管收缩性能相关。

Circulation:肺动脉高压的新机制!

在肺动脉高压(PAH)中,肺血管细胞的过度增殖和凋亡抵抗性是血管重构的重要方面。目前,有一些特定的PAH治疗方法,主要针对内皮功能障碍,但过高的肺动脉压仍然会导致心力衰竭和死亡。肺血管重塑可能由血管细胞的代谢重编程驱动,以增加谷氨酰胺分解和谷氨酸生产。N-甲基-D-天冬氨酸受体(NMDAR)是主要的神经元谷氨酸受体,其也在血管细胞上表达,但其在PAH中的作用未知。近期,一项发表在杂志Circula

JACC:肺动脉高压相关发病率与患者的死亡风险呈明显相关

一般认为,疾病进展过程中出现肺动脉高压(PAH)是预后不好的征兆,然而,PAH相关发病率与预后的相关性没有在随机临床对照试验中证实。本研究的目的旨在用SERAPHIN 和GRIPHON临床研究的数据评估PAH发病事件对后续死亡风险的影响。在SERAPHIN研究中,出现有PAH事件患者3个月的死亡率要高于无PAH事件患者([HR]: 3.39; 95% [CI]: 1.94-5.92)。在GRIPH